BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

20 related articles for article (PubMed ID: 2954605)

  • 1. Secondary treatment of advanced cancer of the prostate with Zoladex.
    Klarskov P; Lund F; Petersen SE
    Int Urol Nephrol; 1990; 22(4):359-62. PubMed ID: 2146234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
    Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
    Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary down-regulation with goserelin (Zoladex) for in vitro fertilisation.
    Tapanainen JS; Hovatta O
    Br J Obstet Gynaecol; 1994 May; 101 Suppl 10():27-8. PubMed ID: 8199101
    [No Abstract]   [Full Text] [Related]  

  • 9. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.